These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 25925044)

  • 1. [Role of VEGF in diseases of the retina].
    Barquet LA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of aflibercept in routine clinical practice].
    Cabrera López F
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():29-34. PubMed ID: 25925049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    García Layana A; Donate López J
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():1-2. PubMed ID: 25925043
    [No Abstract]   [Full Text] [Related]  

  • 4. [New perspectives in the approach to age-related macular degeneration].
    Gallego-Pinazo R; Zapata MA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():11-4. PubMed ID: 25925046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents.
    Li E; Greenberg PB; Voruganti I; Krzystolik MG
    R I Med J (2013); 2016 May; 99(5):15-7. PubMed ID: 27128510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Tsao YC; Chen TY; Wang LA; Lee CC; Lee WA; Hsu SM; Lai CC; Shao SC; Hung JH; Lai EC
    BioDrugs; 2023 Nov; 37(6):843-854. PubMed ID: 37676536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
    Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
    Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina].
    Nakamura S; Hara H
    Yakugaku Zasshi; 2021; 141(12):1307-1317. PubMed ID: 34853203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
    Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
    Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF: A KEY PLAYER NOT ONLY IN MACULAR DEGENERATION. A REVIEW.
    Slíva J
    Cesk Slov Oftalmol; 2020; 76(4):1-3. PubMed ID: 33086850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
    Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
    Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept: an update on recent milestones achieved.
    Palejwala NV; Lauer AK
    Drugs Today (Barc); 2014 Dec; 50(12):779-90. PubMed ID: 25588083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.